Podcasts about nebula genomics

Ted Karkus CEO & Chairman Of The Board Of ProPhase Labs $PRPH   Ticker: PRPH   Website: https://www.prophaselabs.com/ Bio: Ted Karkus Chairman & CEO of ProPhase Labs Ted Karkus, CEO and Chairman of ProPhase Labs, drives the company's diverse and synergistic businesses with his successful track record in biomedical and health companies. He transformed ID Biomedical's strategy and valuation from $25 million to $1.4 billion sale to GlaxoSmithKline. As CEO of ProPhase Labs, he restructured the go-to-market strategy for the flagship product Cold-EEZE, turned around and significantly grew revenues, ultimately selling it for $50 million to Mylan. ProPhase Labs is a fast-growing biotech, genomics and diagnostics company due to its commitment to growth, innovation, and execution excellence outlined in Ted's high growth roadmap. He pivoted into industry leading CLIA labs, and then further diversified by acquiring genomics leader Nebula Genomics. Constantly innovating, Ted then created ProPhase BioPharma to deliver antivirals, cancer tests and therapeutic cancer compounds. The new acquisitions and legacy businesses work to drive synergistic growth with multi-billion-dollar potential. He holds a BS in Psychology from Tufts University with Magna Cum Laude Honors and an MBA in Finance from Columbia University School of Business with Beta Gamma Sigma Honors. --- Support this podcast: https://podcasters.spotify.com/pod/show/smartmoneycircle/support

In today's episode, I speak with Dr. Kamal Obbad, the co-founder of Nebula Genomics. Kamal is a Harvard and Gates-Cambridge Scholar with research experience at Google. Recognizing a gap in the consumer market for Whole Genome Sequencing (WGS), he co-founded Nebula Genomics to democratize access to comprehensive genomic data. Kamal aims to make personal genomics mainstream and accessible. We chat about the significance of whole genome sequencing and its potential to improve health and wellness. Kamal gives us a lesson on what the genome is, the importance of studying the whole genome sequence for health optimization, and why it has previously been so cost prohibitive to secure whole genome sequencing. In this episode you will learn:- Understand the concept of personal genomics and its potential impact on health and wellness.- Learn about the difference between whole genome sequencing and other genetic tests.- Gain knowledge about the complexity of DNA and the importance of non-coding regions in genetic analysis.- Recognize the limitations and concerns associated with genetic testing and the need for genetic counseling.- Explore the future possibilities of DNA sequencing and its role in personalized medicineLearn more about Nebula Genomics and Kamal's work: nebula.org

In which Kamal Obbad, co-founder and CEO of Nebula Genomics, shares his journey founding one of the largest consumer whole genome sequencing services. He also discusses trends in the consumer genomics landscape, the future of genomics research, and the implications of social and technological innovations on genetic privacy. Hosted by Kevin Xu.

In this episode, host Eric Malzone welcomes Kamal Obbad, co-founder of Nebula Genomics, to explore the fascinating world of genetic testing and personalized genomics. Kamal shares insights into Nebula Genomics' mission to make whole genome sequencing more accessible and affordable for consumers, offering tools for exploring their DNA. They discuss the various applications of genetic testing, the importance of actionable genetic information, and the potential impact of AI in data interpretation and counseling. Kamal also delves into the future possibilities of gene editing and its potential implications for human longevity. Join them for an enlightening conversation on the cutting-edge developments in genomics and personalized healthcare.   Links: https://nebula.org/whole-genome-sequencing-dna-test/ https://www.wrkout.com/ 

In a wide-ranging conversation, Leo Laporte talks with Dr. George Church about the history and future of genome sequencing. Dr. Church explains why he is very excited about how they made an organism resistant to all viruses- both known and unknown.   They also talk about:  How Dr. Church made sequencing affordable (from $3BN to $600) Where are we on sequencing the entire human genome, and why would we even want to? How close are we to reversing aging? Should we use gene therapy to double the human lifespan? Why genetically engineering cold-resistant elephants could be important for climate change, and what about ultimately bringing back the Mammoth? He explains the difference between the hype and reality of CRISPR sequencing, synthesis, and delivery What are the privacy concerns about companies sharing your genome? They discuss the controversy and benefit of reconstructing old viruses like the 1918 flu and even inventing new viruses. Dr. Church is a professor of genetics at Harvard Medical School and a pioneer in personal genetics. He is credited with developing the first methods for sequencing the first genome and also the CRISPR technology. He created several companies, including Nebula Genomics and Veritas Genetics. Host: Leo Laporte Guest: Dr. George Church Download or subscribe to this show at https://twit.tv/shows/triangulation.

In a wide-ranging conversation, Leo Laporte talks with Dr. George Church about the history and future of genome sequencing. Dr. Church explains why he is very excited about how they made an organism resistant to all viruses- both known and unknown.   They also talk about:  How Dr. Church made sequencing affordable (from $3BN to $600) Where are we on sequencing the entire human genome, and why would we even want to? How close are we to reversing aging? Should we use gene therapy to double the human lifespan? Why genetically engineering cold-resistant elephants could be important for climate change, and what about ultimately bringing back the Mammoth? He explains the difference between the hype and reality of CRISPR sequencing, synthesis, and delivery What are the privacy concerns about companies sharing your genome? They discuss the controversy and benefit of reconstructing old viruses like the 1918 flu and even inventing new viruses. Dr. Church is a professor of genetics at Harvard Medical School and a pioneer in personal genetics. He is credited with developing the first methods for sequencing the first genome and also the CRISPR technology. He created several companies, including Nebula Genomics and Veritas Genetics. Host: Leo Laporte Guest: Dr. George Church Download or subscribe to this show at https://twit.tv/shows/twit-events. Get episodes ad-free with Club TWiT at https://twit.tv/clubtwit

In a wide-ranging conversation, Leo Laporte talks with Dr. George Church about the history and future of genome sequencing. Dr. Church explains why he is very excited about how they made an organism resistant to all viruses- both known and unknown.   They also talk about:  How Dr. Church made sequencing affordable (from $3BN to $600) Where are we on sequencing the entire human genome, and why would we even want to? How close are we to reversing aging? Should we use gene therapy to double the human lifespan? Why genetically engineering cold-resistant elephants could be important for climate change, and what about ultimately bringing back the Mammoth? He explains the difference between the hype and reality of CRISPR sequencing, synthesis, and delivery What are the privacy concerns about companies sharing your genome? They discuss the controversy and benefit of reconstructing old viruses like the 1918 flu and even inventing new viruses. Dr. Church is a professor of genetics at Harvard Medical School and a pioneer in personal genetics. He is credited with developing the first methods for sequencing the first genome and also the CRISPR technology. He created several companies, including Nebula Genomics and Veritas Genetics. Host: Leo Laporte Guest: Dr. George Church Download or subscribe to this show at https://twit.tv/shows/triangulation.

In a wide-ranging conversation, Leo Laporte talks with Dr. George Church about the history and future of genome sequencing. Dr. Church explains why he is very excited about how they made an organism resistant to all viruses- both known and unknown.   They also talk about:  How Dr. Church made sequencing affordable (from $3BN to $600) Where are we on sequencing the entire human genome, and why would we even want to? How close are we to reversing aging? Should we use gene therapy to double the human lifespan? Why genetically engineering cold-resistant elephants could be important for climate change, and what about ultimately bringing back the Mammoth? He explains the difference between the hype and reality of CRISPR sequencing, synthesis, and delivery What are the privacy concerns about companies sharing your genome? They discuss the controversy and benefit of reconstructing old viruses like the 1918 flu and even inventing new viruses. Dr. Church is a professor of genetics at Harvard Medical School and a pioneer in personal genetics. He is credited with developing the first methods for sequencing the first genome and also the CRISPR technology. He created several companies, including Nebula Genomics and Veritas Genetics. Host: Leo Laporte Guest: Dr. George Church Download or subscribe to this show at https://twit.tv/shows/twit-events. Get episodes ad-free with Club TWiT at https://twit.tv/clubtwit

In a wide-ranging conversation, Leo Laporte talks with Dr. George Church about the history and future of genome sequencing. Dr. Church explains why he is very excited about how they made an organism resistant to all viruses- both known and unknown.   They also talk about:  How Dr. Church made sequencing affordable (from $3BN to $600) Where are we on sequencing the entire human genome, and why would we even want to? How close are we to reversing aging? Should we use gene therapy to double the human lifespan? Why genetically engineering cold-resistant elephants could be important for climate change, and what about ultimately bringing back the Mammoth? He explains the difference between the hype and reality of CRISPR sequencing, synthesis, and delivery What are the privacy concerns about companies sharing your genome? They discuss the controversy and benefit of reconstructing old viruses like the 1918 flu and even inventing new viruses. Dr. Church is a professor of genetics at Harvard Medical School and a pioneer in personal genetics. He is credited with developing the first methods for sequencing the first genome and also the CRISPR technology. He created several companies, including Nebula Genomics and Veritas Genetics. Host: Leo Laporte Guest: Dr. George Church Download or subscribe to this show at https://twit.tv/shows/triangulation.

In a wide-ranging conversation, Leo Laporte talks with Dr. George Church about the history and future of genome sequencing. Dr. Church explains why he is very excited about how they made an organism resistant to all viruses- both known and unknown.   They also talk about:  How Dr. Church made sequencing affordable (from $3BN to $600) Where are we on sequencing the entire human genome, and why would we even want to? How close are we to reversing aging? Should we use gene therapy to double the human lifespan? Why genetically engineering cold-resistant elephants could be important for climate change, and what about ultimately bringing back the Mammoth? He explains the difference between the hype and reality of CRISPR sequencing, synthesis, and delivery What are the privacy concerns about companies sharing your genome? They discuss the controversy and benefit of reconstructing old viruses like the 1918 flu and even inventing new viruses. Dr. Church is a professor of genetics at Harvard Medical School and a pioneer in personal genetics. He is credited with developing the first methods for sequencing the first genome and also the CRISPR technology. He created several companies, including Nebula Genomics and Veritas Genetics. Host: Leo Laporte Guest: Dr. George Church Download or subscribe to this show at https://twit.tv/shows/twit-events. Get episodes ad-free with Club TWiT at https://twit.tv/clubtwit

In this episode, we talk to George Church about his successful career in DNA repair and his entrepreneurial adventures translating research findings into biotech companiesGeorge proudly describes himself as a biologist-engineerHe ponders whether his dyslexia may have helped him by making him realize he was different from others when he was growing upHe looks for projects in ‘exponential fields' that combine pure scientific interest, technology breakthroughs and bring societal benefit.George cautions against using the word ‘impossible'He talks about how he has contributed to scientific and technology revolutionsHe emphasizes the important of considering ethics, safety and security at the outset of ambitious science projectsGeorge remembers how he reacted to having his genome sequenced and speculates about the future of digital genomics and NFTsWhen recruiting, he looks for people that are ‘nice' and have deep knowledge in at least two different fieldsGeorge gets up at 4:30 a.m. and his head is immediately whizzing with new ideasHe tells us how much he learns from his grandchildren (and even mends their party dresses) He mentioned these projects, institutions, companiesHarvard Medical School : https://hms.harvard.edu/ Duke University: https://duke.edu/Harvard University : https://www.harvard.edu/NIH Brain Initiative : https://braininitiative.nih.gov/NIH Centers of Excellence in Genomic Science (CEGS)  : https://www.genome.gov/Funded-Programs-Projects/Centers-of-Excellence-in-Genomic-ScienceWyss Institute  : https://wyss.harvard.edu/Personal Genomes : https://www.personalgenomes.org/TIME 100 Most Influential People : https://time.com/collection/2017-time-100/4742749/george-church/Regenesis: How Synthetic Biology Will Reinvent Nature and Ourselves : https://www.basicbooks.com/titles/george-m-church/regenesis/9780465038657/Nebula Genomics : https://nebula.org/george-church/23andMe : https://www.23andme.com/Biogen : https://www.biogen.com/Gail Martin : https://en.wikipedia.org/wiki/Gail_R._MartinTo find out more about George :Church Lab Website : https://arep.med.harvard.edu/George on Twitter : https://twitter.com/geochurchTo find out more about Renaud : Twitter : https://twitter.com/LePourpre LinkedIn : https://www.linkedin.com/in/renaudpourpre/ To find out more about Jonathan : Twitter : https://twitter.com/Epigenetique LinkedIn : https://www.linkedin.com/in/jonathanweitzman/%20 To learn more about the soundtrack :Music by Amaria - Lovely Swindlerhttps://soundcloud.com/amariamusique/https://twitter.com/amariamusique

Ted Karkus is the CEO of ProPhase Labs, which is in the battle to provide rapid results from PCR tests for COVID-19. While expecting a winter spike, Ted has been surprised at the record-breaking demand the latest Omicron variant has created. ProPhase Labs has recently acquired Nebula Genomics to provide whole genome sequencing direct to consumers to help guide medical treatment and educate people about diseases they may be predisposed to. Ted explains, "So, the issue with regard to turnaround times really has more to do with the number of employees you have, and it's very difficult, particularly in this environment, to find qualified lab techs, particularly in the state of New York, if not across the nation. So, we had these tremendous out-of-the-blue spike COVID incidents. The amount of testing, the request for testing went through the roof. All the labs in the country, and certainly in the state of New York, were overwhelmed." "As you can see, it's not just about the amount of time it takes to process a test with PCR, which is probably four to six hours. It's what the capacity for your lab is. We have three shifts working 24/7, but understand that there was a period in December where the number of specimens that came in, each of our customers, the amount of specimens they sent into us was like double or triple what it had just been a few weeks earlier." "What we do is provide whole genome sequencing direct to consumers. The future of medicine is all about precision medicine or personalized medicine. It's all about using your genetic makeup to understand what are the best drugs and therapies that will optimally work to treat your condition. We provide whole genome sequencing for $300. So, we're the low-cost provider. Right now, our turnaround times are about six weeks." #ProPhaseLabs #COVID19 #COVID #COVIDTesting #PCRCOVIDTest #PCRTest #Omicron ProPhaseLabs.com    Listen to the podcast here

Ted Karkus is the CEO of ProPhase Labs, which is in the battle to provide rapid results from PCR tests for COVID-19. While expecting a winter spike, Ted has been surprised at the record-breaking demand the latest Omicron variant has created. ProPhase Labs has recently acquired Nebula Genomics to provide whole genome sequencing direct to consumers to help guide medical treatment and educate people about diseases they may be predisposed to. Ted explains, "So, the issue with regard to turnaround times really has more to do with the number of employees you have, and it's very difficult, particularly in this environment, to find qualified lab techs, particularly in the state of New York, if not across the nation. So, we had these tremendous out-of-the-blue spike COVID incidents. The amount of testing, the request for testing went through the roof. All the labs in the country, and certainly in the state of New York, were overwhelmed." "As you can see, it's not just about the amount of time it takes to process a test with PCR, which is probably four to six hours. It's what the capacity for your lab is. We have three shifts working 24/7, but understand that there was a period in December where the number of specimens that came in, each of our customers, the amount of specimens they sent into us was like double or triple what it had just been a few weeks earlier." "What we do is provide whole genome sequencing direct to consumers. The future of medicine is all about precision medicine or personalized medicine. It's all about using your genetic makeup to understand what are the best drugs and therapies that will optimally work to treat your condition. We provide whole genome sequencing for $300. So, we're the low-cost provider. Right now, our turnaround times are about six weeks." #ProPhaseLabs #COVID19 #COVID #COVIDTesting #PCRCOVIDTest #PCRTest #Omicron ProPhaseLabs.com    Download the transcript here

In this video Professor Church talks about why everyone should get their complete genome sequenced and how we genetic engineering has created organisms which are immune to all viruses, and how potentially this technology could be used for humans. Nebula Genomics - full genome sequencing company started by Professor Church. https://nebula.org/whole-genome-sequencing-dna-test/ George Church is the Robert Winthrop Professor of Genetics at Harvard Medical School, a Professor of Health Sciences and Technology at Harvard and MIT. Professor Church helped initiate the Human Genome Project in 1984 and the Personal Genome Project in 2005. He is widely recognized for his innovative contributions to genomic science and his many pioneering contributions to chemistry and biomedicine. He has co-authored 580 paper, 143 patent publications & the book "Regenesis". If you would like to support our channel, we'd love a coffee ☕…thank you! https://www.buymeacoffee.com/mhealthspan

MITでビットコインを無料配布した実験、ジョージ・ソロスのプリンター、活版印刷とインキュナブラとレンズ、ミームの原産地、江上不二夫語録、下村脩と1944年のウミホタルについて話しました。Show notes 2014年にMITでビットコインを無料配布した実験 1 2014年にMITでビットコインを無料配布した実験 2 ビットコイン … 仮想通貨 ブロックチェーン Diem … 仮想通貨 Cambridge市にあるbitcoinのATM … 魔法のATM Monk Fish … MITとHarvardの間にある寿司屋。近所に住んでいたが行ったことはない。 CoCo壱の立替払い … Akiなんとか氏のビットコインわらしべ長者物語。Akiなんとか先生、勝手に紹介してすいませんでした。 オードリー・タン … Appleでの時給が1 bitcoinだったという話 ビットコインが入ったHDDを掘る 鉛筆と紙でビットコインをマイニングする 草コイン … researchat.coinつくるしかないじゃないか Nebula Genomics … George Churchの会社？ブロックチェーンとゲノムでほにゃほにゃするらしい。 Turn on, tune in, drop out.　… ティモシーの名言 LSD … イケマセン 僕は君たちに武器を配りたい/瀧本哲史 ジョージ・ソロス エスペラント語 ジョージ・ソロス――投資と慈善が世界を開く 橋本努 インキュナブラ … 1500年までに活版印刷によって刷られた書物のこと。エピソード内では、技術の活版印刷というべきところで、インキュナブラと言ってしまっているケースが複数見られるが、これはインキュナブラと言いたくてしょうがなかったことによるものなのでご容赦いただきたい。 インキュナブラの単数複数形　… incunabulum (単数), incunabula (複数) ホムンクルスの単数複数形　… homunculus (単数), homunculi (複数) 国家錬金術師 … ハガレンのアレ マーシャル・マクルーハン　… The medium is message. の人。実はちゃんと勉強していない… ユークリッドの原論 東方見聞録 42行聖書 … かっこいい 識字 宗教改革 マーティン・ルター Harvard Rare book library ヤンセン父子 … 初めて顕微鏡をつくったといわれている父子 リッペルハイ … 初めて望遠鏡を作ったと言われている人 Researchat.fm ep37 … ロバート・フックやレーウェンフックについてはep37で話しています。 ケプラー … 望遠鏡のところでなんとなくケプラーを引用しましたが、まずはガリレオというべきでした。 ロバート・フック … 初めて顕微鏡でCellを見た人 レーウェンフック … 顕微鏡でさまざまなものを発見した人。例えば微生物など。 畢昇(ひつしょう) … 世界で初めて活版印刷を発明したといわれる北宋の発明家 ベストセラーの本一覧 シュトヘル 西夏文字 トーラー タルムード 風姿花伝 メタルギアソリッドV 波よ聞いてくれ スティーブ・ジョブズ Dynabook Alan Kay … The best way to predict the future is to create it. Zen Yoga 体の柔らかさやストレッチの功罪 … side by side radioさんのどこかでお話されていたと思います！ よみ人知らず 君が代 芭蕉の句とハイビジョンＴＶとでは、どちらの情報量が多いか。by 石井裕先生 江上不二夫 科学者の卵たちに贈る言葉－江上不二夫が伝えたかったこと … 江上不二夫語録 三菱生命研 アガロース 荒木長次先生のアガロースに関する初期の論文 実験に用いる寒天について、食用寒天 下村脩 ウミホタル ウッズホール海洋生物学研究所 … 通称MBL。さまざまなノーベル賞級の発見を推進し、また細胞分子生物学のコミュニティーを発展させてきた。日本人研究者としてはShinya Inoue先生やOsamu Shimomura先生の著しい業績が思い起こされる。下記の三崎の臨海実験所関連でいえばKatsuma Dan先生のThe last one to goもはずせない。 The last one to go トーマス・ハント・モーガン … ショウジョウバエ研究、そして遺伝学研究の始祖 Edmund Harvey Frank Johnson … 下村先生のアドバイザー 三崎臨海実験所 ロバート・ボイル … ボイルシャルルの法則のボイル 羽根田弥太 国立科学博物館 … 地下一階にウミホタルのボトルがある。 Editorial notes ホゲラホゲラホゲラ(soh) とりあえず詠み人知らずのインキュナブラって言いたかったんだ… (tadasu) 結構印刷周りで断定的な言い方をしていますが、僕の個人的な感想です(coela)

Dr. Dennis Grishin is the Chief Scientific Officer at Nebula Genomics and a Boehringer Ingelheim Ph.D. Fellow in Genetics and Genomics at Harvard University

Nebula Genomics to partner with Oasis Labs and Akon to mint DNA data as NFTs. The move is said to be a play to help democratize the monetization of heath data, though time will tell how it all plays out. Source Article: https://www.coindesk.com/monetizing-genomic-data-nfts-latest-use-case Native Assets is a blockchain firm specializing in educational seminars, detailed research, indusutry analysis & corporate advising. Our mission? To empower you with the knowledge & insights to navigate + flourish in the new digital era - the blockchain era. --- Become A Student https://www.nativeassets.co/foundatations Join Our Private Network https://www.nativeassets.co/privatenetwork Connect With Us https://www.linkedin.com/company/nativeassets/ Become An Affiliate https://www.nativeassets.co/Affiliate For More Visit https://www.nativeassets.co/ --- Send in a voice message: https://anchor.fm/nativeassets/message

News this week: ONC releases its plan to reduce documentation burdens. Training investments paid off for OrthoVirginia (and measuring provider EMR satisfaction is important). Significant article out of Annals of Internal Medicine showing that usage of primary care decreased 24% from 2008 to 2016; important for CMIOs to follow trends in practice patterns. Landmark trial out of the Journal of AHA about SGLT2 inhibitors and its role in primary and secondary intervention of cardiovascular events; will probably impact our clinical decision support tools sooner rather than later. Nebula Genomics offers $299 whole genome sequencing; what are we going to do with all that data?!?!? Those stories and more on this episode of CMIO Podcast.

Health Unchained Links Website: healthunchained.org Telegram: t.me/healthunchained Twitter: twitter.com/Healthunchaind Udemy Blockchain/Healthcare Course (Promo Code DOGUM2019): https://www.udemy.com/blockchain-and-healthcare/?couponCode=DOGUM2019 Subscribe to the top blockchain/healthcare newsletter delivered every week by Robert Miller: bert.substack.com/ ConVerge2Xcelerate Conference (Oct. 15, 2019) Registration Link: conv2x-2019.eventcreate.com/ Coupon Code: HEALTHUNCHAINED EPISODE 48 - SHOW NOTES •Daniel Uribe, Serial Entrepreneur, CEO & Co Founder of Genobank.io, Bs Electronics & Telecom, MBA, EP Stanford GSB, SingularityU •Executive Program at Singularity Univeristy - https://su.org •Navigating the healthcare industry •The idea for Genobank.io was inspired by Daniel’s son •Cybersecurity in Healthcare •General technical specifications (architecture) of Genobank oBlockchain tools - https://counterparty.io odata marketplace oprivacy and security oprivate network storage using IPFS oERC-20 and ERC-721 tokenomics •Platform Competition - Thoughts on Nebula Genomics, Encrypgen, and others •Working with Oasis Labs and NuCypher •DNA Extraction Kits and distribution •https://www.wsj.com/articles/justice-department-weighs-collecting-dna-from-migrants-in-custody-11570055457 •Branded kits for Clinical Trials partnerships in Mexico •Customers - adoption challenges / traction / opportunities •Ethical considerations of DNA data ownership •Genobank Team •Roadmap •If you had to have micro chip implanted in your body, where would you want it to be implanted? Favorite Scientist or businessperson News Corner https://finance.yahoo.com/news/burstiq-closes-5-5-million-140000286.html On October 1, 2019, Denver based BurstIQ announced a $5.5 million Series A capital raise with Elsewhere partners to fund the 4 year old healthcare/blockchain startup and grow it’s service offerings for enterprise-level organizations. This is the 2nd largest raise this for a healthcare/blockchain startup following the $16m raise by Chronicled. The total funding for blockchain and healthcare startups in 2019 so far is about $37m.

Sanjeev Wadhwa, Founder and CEO of Life Singularity. Life singularity is a startup looking to ultimately create A Virtual Assistant for every individual on the planet using AI/VR/blockchain to drive precision health. Sanjeev was a partner at Ernst & Young, CSC (partner technology, director RD Life sciences), Show Notes •Learning how to scale at Johnson & Johnson as a program Director 1993-2000 •What drives you to the healthcare industry? •Life Singularity'sAI/VR/Blockchain platform was accepted (Top 20 out of 500 startups) for 2018 Healthcare Innovation Lab for MEDy (Medical Entrepreneurship and Disruption) awards competition at Healthcare Innovation Lab at Exponential medicine (https://exponential.singularityu.org/medicine/), November 2018 in San Diego. •What is the vision for Life Singularity? Why did you start it? How big is the company? Naming the company. •Life Singularity’s collective intent is to help guide the patient’s holistic health •VC perspective - Tackling too many services/technologies for a startup •What is the current state of AI in healthcare? •What kind of data can be collected in our exposome, behavome? •Using geospatial monitoring •Juhan Sonin – social determinants of health Ep. 20. Personal choice (individual behavior) 40%, Genetics 30%, medical care 10%, environment 5%, social 15% https://soundcloud.com/healthunchained/designing-better-healthcare-juhan-sonin-goinvo •Can you describe your technology stack? •Blockchain adoption and awareness in healthcare •What are the biggest barriers to blockchain adoption? •Who are your company partners and major customers? •What kind of traction have you had so far? •What is Life Singularity's business model? •Can you discuss any patents that Life singularity may have filed or granted? •Explain the type of VR that your platform offers. •What does the future of VR look like? •How is life singularity handing consumer data privacy? •Who do you consider your competitors? How are you different? What about google who has so much data? •Were there any events or announcements in the healthcare/blockchain space that was very unexpected or surprising to you? Why? News corner https://nebula.org/anonymous-sequencing Anonymous genome sequencing and the recent announcement from Nebula Genomics to offer tips and tricks to protect your privacy. Tips they provide on their website include: •Using cryptocurrencies or a pre-paid debit card to make the initial purchase of the Saliva Test-kit •Using a secure email service like Protonmail •Using a VPN to give you another IP address to browse the internet •Reserve a PO box from USPS I’ve interviewed professor George Church, who co-founded Nebula Genomics: https://soundcloud.com/healthunchained/ep-9-decentralized-whole-genome-sequencing-george-church-nebula-genomics Health Unchained Links Website: healthunchained.org Telegram: t.me/healthunchained Twitter: twitter.com/Healthunchaind Udemy Blockchain/Healthcare Course (Promo Code DOGUM2019): https://www.udemy.com/blockchain-and-healthcare/?couponCode=DOGUM2019 Subscribe to the top blockchain/healthcare newsletter delivered every week by Robert Miller: bert.substack.com/ ConVerge2Xcelerate Conference (Oct. 15, 2019) Registration Link: conv2x-2019.eventcreate.com/ Service Code: HEALTHUNCHAINED

— Coinbase looking to add additional 17 cryptos — Iran to propose new crypto mining regulations — Nebula Genomics launch blockchain-based DNA sequencing — Genesis Trading acquires Qu Capital — BoA joins Marco Polo blockchain trade network — Zap launches in-app OTC desk for Bitcoin — Total crypto market cap spikes to $273B

Dennis Grishin is the Co-Founder & Chief Scientific Officer of Nebula Genomics which is a privacy-focused personal genomics company. Dennis is a PhD candidate at Harvard Medical School doing research on genomic data privacy. https://nebula.org Twitter ► https://twitter.com/NebulaGenomics ******* Simulation is rebirthing the public intellectual by hosting the greatest multidisciplinary minds of our time. Build the future. Architect the frameworks and resource flows to maximize human potential. http://simulationseries.com ******* SUBSCRIBE TO SIMULATION ► YOUTUBE: http://bit.ly/SimYoTu ITUNES: http://bit.ly/SimulationiTunes INSTAGRAM: http://bit.ly/SimulationIG TWITTER: http://bit.ly/SimulationTwitter ******* FACEBOOK: http://bit.ly/SimulationFB SOUNDCLOUD: http://bit.ly/SimulationSC LINKEDIN: http://bit.ly/SimulationLinkedIn PATREON: http://bit.ly/SimulationPatreon CRYPTO: http://bit.ly/SimCrypto ******* NUANCE-DRIVEN DISCOURSE ► http://bit.ly/SimulationTG WATCH ALLEN'S TEDx TALK ► http://bit.ly/AllenTEDx FOLLOW ALLEN ► INSTAGRAM: http://bit.ly/AllenIG TWITTER: http://bit.ly/AllenT ******* LIST OF THOUGHT-PROVOKING QUESTIONS ► http://simulationseries.com/the-list GET IN TOUCH ► simulationseries@gmail.com

Kamal Obbad, CEO and cofounder of Nebula Genomics (nebula.org), delivers a thorough overview of the current state of genomic data, research, and what the future holds for the study of the genome. As a self-described Harvard graduate and Cambridge University computer science dropout, Kamal Obbad has definitely taken his own path to success. Obbad is a passionate biotech entrepreneur whose keen interest in both tech, and helping others, led to his cofounding of Nebula Genomics. Obbad discusses the mission of his company—to make genomic data extraordinarily useful for medical researchers. Getting their start at Harvard Medical School in the lab of fellow cofounder George Church, known as the "father of synthetic biology,” the entrepreneurs set out to expand the opportunities for genomic data to be used. From data driven clinical decision making to drug design, Obbad discusses the possibilities. He provides detailed information on sequencing genomes, explaining how a genome can be read, and what information can be gathered through the process. The science tech entrepreneur talks about how genomes are utilized in the study of diseases, and the mechanisms of genetic change. Obbad states that there are many barriers to getting genomic data, from regulation to personal fears about revealing one's genomic data. Genomics, specifically stated, is the interdisciplinary field of biology that focuses on the structure, mapping, function, evolution, and editing of genomes. And a genome is an organism's comprehensive set of DNA that includes all of its genes. Obbad discusses data sets that are accessible and the challenges to gather the appropriate amount of data in aggregate. Obbad states, when individuals use genetic data companies such as 23andMe and others, to gather personal information they are curious about, what the individuals are really doing is paying these companies for the privilege to resell this genetic data. Because of the many aforementioned problems and challenges, Obbad and his co-founding partners have decided to take Nebula Genomics in an entirely different direction, better for everyone involved. As they state, the future of health is in your DNA. Nebula Genomics allows users to contribute to significant medical breakthroughs and get rewarded for it, unlike other companies who may sell your data and provide you with no real compensation in any form. Nebula Genomics stands firmly on the idea that everyone should understand their genes, and truly own their personal health data. As such, Nebula Genomics has reinvented the genomic data business model, utilizing blockchain to connect data buyers with data users, and liberating genomic data by bringing records to a single network where researchers can gain critical access.

In November 2018, Associated Press shocked the global medical community with a news from China: A Chinese researcher claimed that he helped make the world’s first genetically edited babies. He edited the genes of twins with CRISPR/Cas9 technology, with the aim to make the babies resistant to possible future infection with HIV, the AIDS virus. The medical community was more or less unanimous in condemnation of the act because CRISPR technology is so new. This was not the only news that resonated in global news in December: the startup Nebula Genomics announced it is offering free genome sequencing, in which the ownership and control of the data would be in individual's hands. Furthermore, patients could make money with their data, as the company predicts that companies and research organizations would be willing to pay for the cost of sequencing if in exchange they also get some key medical information about the person involved.  The expert in this episode is Natalie Pankova. Natalie has a medical background but currently work as a COO of SHIVOM - a global genomics blockchain company, targeting developing countries first, to discover the genetic specifics of various ethnicities, which could improve drug development and help uncover, why certain ethnicities don’t respond to specific drugs. 

In 2018, people started using the blockchain to battle deepfakes, track sushi-grade tuna from Fiji to Brooklyn, and even cast a (symbolic) vote. It was only a matter of time before someone figured out how to put all 6 billion bits of your genetic source code on the blockchain too. Starting this week, a startup called Nebula Genomics is doing just that, offering whole-genome sequencing for free, as a way to stock up for its real ploy: a blockchain-based genetic marketplace.

Distributed Health 2018 mini interviews 1. Kamal Obbad – CEO of Nebula Genomics (https://www.nebula.org/) 2. Tyler Penrod – CTO at Recovery Unplugged (https://www.recoveryunplugged.com/) 3. Jason O’Meara - Senior Director of Architecture at Quest Diagnostics discussing the Synaptic Alliance (https://www.synaptichealthalliance.com/) 4. Teresa J. Walker – Law Firm Management Guru and COO of Waller Lansden Dortch & Davis, LLP (http://www.wallerlaw.com/) 5. Cory Pitt – Personal Digital Spaces 6. David Boswell – Developer/Director of Ecosystem at Hyperledger Linux Foundation 7. Himanshu Verma – CEO of Consilx (http://www.consilx.com/) 8. Jason Bierly, CPA - Senior Tax Manager at Aprio (https://www.aprio.com/) 9. Najib Ben Brahim – CEO Telehealth Management LLC (https://www.telehealthmgt.com/) 10. JC Crawford – Networking Sales Specialist (Tennessee) Citrix (https://www.citrix.com/) 11. Khrys Hatch - Capital Formation Research Coordinator at Launch Tennessee (https://launchtn.org/) 12. Dominique Hurley – VP, Strategic Partnerships and Innovation at HealthVerity (https://healthverity.com/) 13. Dr. Tal Rapke – Founder and CEO of ScalaMed (Winner of Distributed Health 2018 Investor Pitch Competition) (https://www.scalamed.com/)

George Church, professor at Harvard & MIT, co-author of 480 papers, 130 patent publications & one book "Regenesis", originally published in 2012. His contributions have enabled nearly all advancements in “next generation” DNA sequencing methods, he’s cofounded over 20 companies and he was listed as one of TIME’s 100 most influential people of 2017. Also considered the father of synthetic biology. George M. Church - http://arep.med.harvard.edu/gmc/ Nebula Genomics - https://www.nebulagenomics.io/ Veritas Genetics - https://www.veritasgenetics.com/ Show Notes • Nebula Genomics origins and Veritas Genetics traction • Genotyping vs. Medical grade whole genome sequencing – prices, value, and utility • Data ownership of personal genomes • Personal Genome Project is an open source/open access collaboration to share genomic and phenotypic information with researchers • 3 Axes: How close to useful medical genome (technically); who controls it (self or corporate); how useful on a day-to-day basis (understandability and interactivity). • Genome sequencing technology adoption and Seat-belts • What scientific and social problems are you most concerned or obsessed with today? • Aging Reversal • Human life extension limitations and perceptions • How Genome sequencing is like the internet back in the late 1980s. • Genome editing risks and biohacking ethics • Equitable distribution of gene editing technology among all the people require lower cost • What’s more important- Information Systems R&D or microbiology wet-lab experiments? How dependent are they on each other? • How did you first hear about blockchain technology? • Personal Genetics Education Project - PGed.org • Cambrian explosion of blockchains • Exploring possibilities of genomic research • What is the basis of consciousness? • George’s favorite scientists Quick Quote: Decoding the human genome sequence is the most significant undertaking that we have mounted so far in an organized way in all of science. I believe that reading our blueprints, cataloguing our own instruction book, will be judged by history as more significant than even splitting the atom or going to the moon. -Francis S. Collins [Director of the National Institute of Health (NIH)] News Corner 23andMe announces $300M deal for your DNA with giant drug company GSK - https://www.digitaltrends.com/cool-tech/23andme-gsk-drugs/